

TDMS No. 20310 - 01	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]	Date Report Requested: 07/22/2009
Test Type: 26-39 WEEKS	3'-Azido-3'-deoxythymidine (AIDS)	Time Report Requested: 11:52:38
Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

TDMS No. 20310 - 01	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]	Date Report Requested: 07/22/2009
Test Type: 26-39 WEEKS	3'-Azido-3'-deoxythymidine (AIDS)	Time Report Requested: 11:52:38
Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

TDMS No. 20310 - 01	P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]	Date Report Requested: 07/22/2009
Test Type: 26-39 WEEKS	3'-Azido-3'-deoxythymidine (AIDS)	Time Report Requested: 11:52:38
Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

Test Type: 26-39 WEEKS	3'-Azido-3'-deoxythymidine (AIDS)	Time Report Requested: 11:52:38
Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

Test Type: 26-39 WEEKS	3'-Azido-3'-deoxythymidine (AIDS)	Time Report Requested: 11:52:38
Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

Route: GAVAGE	CAS Number: 30516-87-1	First Dose M/F: NA / 11/18/04
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)		Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd) **Lab:** NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd) **Lab:** NCTR

C Number: C20310C

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups:	Include 912 Vehicle 9 mo F	Include 913 AZT 40 9 mo F	Include 914 AZT 80 9 mo F
	Include 915 AZT 120 9 mo F		

Study Gender: Female

TDMSE Version: 2.1.0

Test Type: 26-39 WEEKS

Time Report Requested: 11:52:38

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Disposition Summary				
Animals Initially in Study	26	27	27	27
Early Deaths				
Moribund Sacrifice	1			1
Natural Death		1	1	
Survivors				
Moribund Sacrifice	1	2	1	2
Natural Death	1	1	1	3
Terminal Sacrifice	23	23	24	21
Animals Examined Microscopically	26	27	27	27

ALIMENTARY SYSTEM

Esophagus	(26)	(27)	(27)	(27)
Adventitia, Necrosis		1 [2.0]		
Intestine Large, Cecum	(25)	(27)	(25)	(24)
Hyperplasia, Lymphoid	2 [2.5]	2 [2.0]	3 [2.0]	2 [2.0]
Epithelium, Hyperplasia			1 [2.0]	
Intestine Large, Colon	(26)	(26)	(27)	(25)
Intestine Large, Rectum	(25)	(27)	(27)	(25)
Hyperplasia, Lymphoid		1 [2.0]	1 [3.0]	
Intestine Small, Ileum	(25)	(27)	(25)	(25)
Intestine Small, Jejunum	(25)	(27)	(25)	(25)
Liver	(26)	(27)	(27)	(27)
Basophilic Focus				1 [2.0]
Hematopoietic Cell Proliferation			1 [1.0]	
Infiltration Cellular, Lymphocyte				1 [1.0]
Inflammation, Chronic Active		2 [1.0]	1 [1.0]	
Necrosis			1 [1.0]	
Tension Lipidosis	3 [1.0]	5 [1.6]	7 [1.1]	4 [1.0]
Vacuolization Cytoplasmic	6 [1.2]	4 [1.0]	3 [1.3]	10 [1.0]
Mesentery	(1)	(0)	(1)	(1)
Hemorrhage	1 [3.0]			1 [3.0]
Fat, Necrosis			1 [3.0]	1 [4.0]
Pancreas	(26)	(27)	(27)	(26)
Cytoplasmic Alteration				1 [1.0]
Infiltration Cellular, Lymphocyte			1 [1.0]	3 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:52:38

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Acinar Cell, Degeneration			1 [1.0]	1 [2.0]
Salivary Glands	(26)	(27)	(26)	(27)
Infiltration Cellular, Lymphocyte	15 [1.2]	14 [1.1]	10 [1.3]	10 [1.0]
Stomach, Forestomach	(26)	(27)	(27)	(27)
CARDIOVASCULAR SYSTEM				
Heart	(26)	(27)	(27)	(26)
Bacterium		1		
Congestion			2 [2.5]	
Inflammation, Chronic Active	1 [1.0]		1 [1.0]	1 [4.0]
Pericardium, Necrosis		1 [2.0]		
ENDOCRINE SYSTEM				
Adrenal Cortex	(26)	(27)	(27)	(26)
Subcapsular, Hyperplasia	25 [1.0]	25 [1.2]	27 [1.2]	24 [1.2]
Parathyroid Gland	(21)	(22)	(22)	(22)
Cyst		1 [1.0]		
Pituitary Gland	(26)	(27)	(27)	(27)
Thyroid Gland	(25)	(27)	(27)	(26)
Cyst		1 [1.0]		
Degeneration	1 [1.0]	2 [1.0]		
Ectopic Thymus		2		1
GENERAL BODY SYSTEM				
Tissue NOS	(0)	(1)	(0)	(1)
Mediastinum, Abscess				1 [4.0]
Mediastinum, Foreign Body				1
GENITAL SYSTEM				
Clitoral Gland	(25)	(26)	(26)	(27)
Degeneration				1 [3.0]
Ovary	(26)	(27)	(27)	(26)
Cyst		1 [1.0]	1 [2.0]	1 [2.0]
Pigmentation				1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:52:38

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Bilateral, Cyst			1 [2.0]	
Uterus	(26)	(27)	(27)	(27)
Edema				1 [3.0]
Infiltration Cellular, Polymorphonuclear	1 [2.0]	3 [2.3]	3 [2.0]	3 [2.0]
Endometrium, Hyperplasia, Cystic	3 [1.3]	4 [2.0]	5 [2.0]	5 [1.6]
Lumen, Dilatation	10 [1.2]	12 [1.3]	14 [1.6]	8 [1.3]
HEMATOPOIETIC SYSTEM				
Bone Marrow	(26)	(26)	(26)	(26)
Myeloid Cell, Hyperplasia			4 [2.5]	1 [2.0]
Lymph Node	(1)	(1)	(0)	(3)
Lumbar, Hyperplasia, Lymphoid	1 [2.0]			1 [2.0]
Lymph Node, Mandibular	(26)	(27)	(25)	(26)
Hyperplasia, Lymphoid			2 [2.5]	
Lymph Node, Mesenteric	(26)	(26)	(26)	(27)
Hyperplasia, Lymphoid	8 [1.4]	6 [1.8]	6 [1.3]	6 [1.7]
Spleen	(26)	(26)	(27)	(27)
Hematopoietic Cell Proliferation	5 [2.8]	4 [2.0]	5 [3.0]	8 [3.0]
Hyperplasia, Lymphoid	4 [2.0]	5 [2.2]	7 [2.4]	6 [1.8]
Thymus	(24)	(26)	(23)	(27)
Bacterium		1		
Foreign Body		1		
Hyperplasia, Lymphoid	3 [2.0]	2 [2.0]	3 [2.0]	2 [2.0]
Inflammation, Chronic Active				1 [3.0]
Necrosis		1 [4.0]		
INTEGUMENTARY SYSTEM				
Mammary Gland	(25)	(26)	(27)	(27)
Alveolus, Hyperplasia		1 [2.0]		
Skin	(26)	(27)	(27)	(27)
MUSCULOSKELETAL SYSTEM				
Bone	(0)	(1)	(0)	(1)
Bone, Femur	(26)	(27)	(27)	(27)
Skeletal Muscle	(26)	(27)	(27)	(27)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:52:38

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Atrophy	2 [2.0]			
Cyst	1 [4.0]			
NERVOUS SYSTEM				
Brain, Brain Stem	(26)	(27)	(27)	(27)
Glios		1 [3.0]		
Brain, Cerebrum	(26)	(27)	(27)	(27)
Compression				1 [2.0]
Infiltration Cellular, Lymphocyte		1 [1.0]		
Mineralization		1 [1.0]	4 [1.0]	2 [1.0]
Peripheral Nerve	(2)	(0)	(0)	(0)
Axon, Degeneration	2 [2.5]			
Spinal Cord	(1)	(0)	(0)	(0)
Axon, Degeneration	1 [2.0]			
RESPIRATORY SYSTEM				
Lung	(26)	(27)	(26)	(27)
Abscess				1 [4.0]
Bacterium		1		
Foreign Body				1
Inflammation, Chronic Active				1 [3.0]
Necrosis				1 [2.0]
Mediastinum, Foreign Body		1		
Mediastinum, Necrosis		1 [3.0]		
Nose	(26)	(27)	(27)	(27)
SPECIAL SENSES SYSTEM				
Eye	(25)	(25)	(26)	(24)
Cataract	1 [1.0]			
Harderian Gland	(26)	(27)	(27)	(25)
URINARY SYSTEM				
Kidney	(26)	(27)	(27)	(27)
Casts Protein	1 [1.0]	1 [1.0]	3 [1.0]	2 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:52:38

Route: GAVAGE

First Dose M/F: NA / 11/18/04

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Cyst	1 [1.0]			1 [1.0]
Glomerulosclerosis				1 [3.0]
Hydronephrosis			1 [4.0]	
Infiltration Cellular, Lymphocyte	9 [1.1]	6 [1.2]	5 [1.0]	4 [1.0]
Inflammation, Suppurative			1 [4.0]	
Metaplasia, Osseous		1 [1.0]		
Mineralization	1 [1.0]			
Nephropathy			1 [4.0]	1 [3.0]
Ureter	(0)	(0)	(1)	(0)
Inflammation, Suppurative			1 [3.0]	
Lumen, Dilatation			1 [2.0]	
Urinary Bladder	(26)	(27)	(27)	(26)
Infiltration Cellular, Lymphocyte	1 [1.0]	4 [1.0]	2 [1.0]	1 [1.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)